Literature DB >> 20712409

The origins of oxidant stress in Parkinson's disease and therapeutic strategies.

Dalton James Surmeier1, Jaime N Guzman, Javier Sanchez-Padilla, Joshua A Goldberg.   

Abstract

Parkinson's disease (PD) is a major world-wide health problem afflicting millions of the aged population. Factors that act on most or all cell types (pan-cellular factors), particularly genetic mutations and environmental toxins, have dominated public discussions of disease etiology. Although there is compelling evidence supporting an association between disease risk and these factors, the pattern of neuronal pathology and cell loss is difficult to explain without cell-specific factors. This article focuses on recent studies showing that the neurons at greatest risk in PD-substantia nigra pars compacta dopamine neurons-have a distinctive physiological phenotype that could contribute to their vulnerability. The opening of L-type calcium channels during autonomous pacemaking results in sustained calcium entry into the cytoplasm of substantia nigra pars compacta dopamine neurons, resulting in elevated mitochondrial oxidant stress and susceptibility to toxins used to create animal models of PD. This cell-specific stress could increase the negative consequences of pan-cellular factors that broadly challenge either mitochondrial or proteostatic competence. The availability of well-tolerated, orally deliverable antagonists for L-type calcium channels points to a novel neuroprotective strategy that could complement current attempts to boost mitochondrial function in the early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712409      PMCID: PMC3048813          DOI: 10.1089/ars.2010.3521

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  127 in total

Review 1.  Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Curr Opin Neurol       Date:  2007-08       Impact factor: 5.710

2.  Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.

Authors:  Jeffrey H Kordower; Yaping Chu; Robert A Hauser; Thomas B Freeman; C Warren Olanow
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

3.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase.

Authors:  Eva Andres-Mateos; Celine Perier; Li Zhang; Beatrice Blanchard-Fillion; Todd M Greco; Bobby Thomas; Han Seok Ko; Masayuki Sasaki; Harry Ischiropoulos; Serge Przedborski; Ted M Dawson; Valina L Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-31       Impact factor: 11.205

4.  Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin.

Authors:  Nicole Exner; Bettina Treske; Dominik Paquet; Kira Holmström; Carola Schiesling; Suzana Gispert; Iria Carballo-Carbajal; Daniela Berg; Hans-Hermann Hoepken; Thomas Gasser; Rejko Krüger; Konstanze F Winklhofer; Frank Vogel; Andreas S Reichert; Georg Auburger; Philipp J Kahle; Bettina Schmid; Christian Haass
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 5.  Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

Authors:  Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2008-01       Impact factor: 44.182

6.  Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.

Authors:  Tohru Kitada; Antonio Pisani; Douglas R Porter; Hiroo Yamaguchi; Anne Tscherter; Giuseppina Martella; Paola Bonsi; Chen Zhang; Emmanuel N Pothos; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

7.  Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.

Authors:  Ivar Mendez; Angel Viñuela; Arnar Astradsson; Karim Mukhida; Penelope Hallett; Harold Robertson; Travis Tierney; Renn Holness; Alain Dagher; John Q Trojanowski; Ole Isacson
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

8.  Use of antihypertensives and the risk of Parkinson disease.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Neurology       Date:  2008-02-06       Impact factor: 9.910

Review 9.  Multiple dopamine functions at different time courses.

Authors:  Wolfram Schultz
Journal:  Annu Rev Neurosci       Date:  2007       Impact factor: 12.449

Review 10.  Parkinson's disease: a dual-hit hypothesis.

Authors:  C H Hawkes; K Del Tredici; H Braak
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-24       Impact factor: 8.090

View more
  68 in total

1.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 2.  Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.

Authors:  Lucio G Costa; Rian de Laat; Khoi Dao; Claudia Pellacani; Toby B Cole; Clement E Furlong
Journal:  Neurotoxicology       Date:  2013-09-04       Impact factor: 4.294

3.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

4.  Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.

Authors:  Nadine J Ortner; Gabriella Bock; Antonios Dougalis; Maria Kharitonova; Johanna Duda; Simon Hess; Petronel Tuluc; Thomas Pomberger; Nadia Stefanova; Florian Pitterl; Thomas Ciossek; Herbert Oberacher; Henning J Draheim; Peter Kloppenburg; Birgit Liss; Jörg Striessnig
Journal:  J Neurosci       Date:  2017-06-07       Impact factor: 6.167

5.  Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response.

Authors:  Rahul Srinivasan; Christopher I Richards; Cheng Xiao; Doreen Rhee; Rigo Pantoja; Dennis A Dougherty; Julie M Miwa; Henry A Lester
Journal:  Mol Pharmacol       Date:  2012-02-29       Impact factor: 4.436

6.  Creatine Protects Against Cytosolic Calcium Dysregulation, Mitochondrial Depolarization and Increase of Reactive Oxygen Species Production in Rotenone-Induced Cell Death of Cerebellar Granule Neurons.

Authors:  Sofia Fortalezas; Dorinda Marques-da-Silva; Carlos Gutierrez-Merino
Journal:  Neurotox Res       Date:  2018-08-09       Impact factor: 3.911

Review 7.  Nanotechnology: toxicologic pathology.

Authors:  Ann F Hubbs; Linda M Sargent; Dale W Porter; Tina M Sager; Bean T Chen; David G Frazer; Vincent Castranova; Krishnan Sriram; Timothy R Nurkiewicz; Steven H Reynolds; Lori A Battelli; Diane Schwegler-Berry; Walter McKinney; Kara L Fluharty; Robert R Mercer
Journal:  Toxicol Pathol       Date:  2013-02-06       Impact factor: 1.902

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Presynaptic L-Type Ca2+ Channels Increase Glutamate Release Probability and Excitatory Strength in the Hippocampus during Chronic Neuroinflammation.

Authors:  Giorgia Giansante; Antonella Marte; Alessandra Romei; Cosimo Prestigio; Franco Onofri; Fabio Benfenati; Pietro Baldelli; Pierluigi Valente
Journal:  J Neurosci       Date:  2020-08-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.